Abraham A, Pati R, Galivan JH, McGuire JJ, Kisliuk RL, Hausheer FH, Nair MG. Aldehyde oxidase mediated 7-hydroxylation of antifolates and its therapeutic relevance. Cell Pharmacol. 3: 29-34, 1996

Azizkhan JC, Lin SY, Jensen DE, Kostic D, Black AR. Retinoblastoma protein, gene expression, and cell cycle control., In Cancer Genes: Functional Aspects., Mihich E, Housman D, eds., NY, Plenum Press, 1996, Chapter 10, pp. 177-191

Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Wrzosek K, Swann VL, Minderman H, Block AM, Pixley LA, Christiansen NP, Fay JW, Barcos M, Rustum YM, Herzig GP, Bloomfield CD. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood, 87(4):1484-1494, 1996

Black AR, Azizkhan JC. Transcriptional regulation of growth-related genes by E2F and Sp1. The Pezcoller Foundation Journal 3:4-16, 1996

Black A, Dolnick B. Expression of rTS correlates with altered growth regulation of thymidylate synthase . Cancer Res., 56:700-705, 1996

Chiang SY, Welsh J, Rauscher FJ III, Beerman TA. Effect of DNA binding drugs on EGR1 and TBP complex formation with the Herpes Simplex Virus Latency promoter. J. Biol. Chem. 271: 23999-24004, 1996

Cao S, Abraham A, Nair G, Pati R, Galivan JH, Hausheer FH, Rustum YM. Polyglutamylation of the dihydrofolate reductase *-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin. Cancer Research, Vol. 2: 707-712, 1996

Cao S, Frank C, Rustum YM. Role of fluoropyrimidines and dose of leucovorin in a preclinical model. J. Natl. Cancer Institute, 88(7):430-436, 1996

Cobuzzi R, Burhans W, Beerman TA. Inhibition of Initiation of simian virus 40 by DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin. J. Biol. Chem., 271(33):19852-19859, 1996

Creaven PJ, Rustum YM, Henderson ES. Chemotherapy: Pharmacologic principles and pharmacology of anticancer drugs. In: Leukemia, Sixth Edition, E.W. Henderson, T.A. Lister and M.F. Greaves, eds., W.B. Saunders Publ., 1996, pp. 313-353

Dolnick B, Black A. Alternate splicing of the rTS Gene Product and its overexpression in a 5-fluorouracil-resistant cell line. Cancer Res. 56:3207-3210, 1996

Dolnick B, Black A, Winkler P, Schindler K, Hsueh CT. rTS gene expression is associated with altered regulation of thymidylate synthase and sensitivity to fluorinated pyrimidines. In: Advances in Enzyme Regulation, Vol. 36, 165-180, 1996

Ehrke M J, Mihich E. Immunopharmacology of anticancer agents, In: Immunopharmacology Reviews, Vol. 2, (J.W. Hadden and A. Szentivanyi, eds., ). Plenum Publ. Corp, New York, Chapter 4, pgs. 103-127, 1996

Ehrke MJ, Verstovsek S, Zaleskis G, Ho RLX, Ujhazy P, Maccubbin D, Mihich E. Specific Anti-EL4 lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunology and Immunotherapy 42: 221-230, 1996

Fogel-Petrovic M, Vujcic S, Brown PJ, Haddox MK, Porter CW. Effects of polyamines, polyamine analogs, and inhibitors of protein synthesis on spermidine-spermine N1-acetyltransferase gene expression, Biochemistry, 35:14436-14444, 1996

Fogel-Petrovic M, Vujcic S, Häner R, Regenass U, Mett H, Porter CW. Sequence specific antisense oligonucleotide analog interference with spermidine/spermine N1-acetyltransferase gene expression, Anticancer Res., 16:2517-2524, 1996

Fogel-Petrovic M, Vujcic S, Miller J, Porter CW. Differential post-transcriptional control of ornithine decarboxylase and spermidine-spermine N1-acetyltransferase by polyamines, FEBS Lett., 391:89-94, 1996

Freedman AN, Michalek AM, Marshall JR, Mettlin CJ, Petrelli N, Black JD, Zhang ZF, Satchidanand SKS, and Asirwathan JE. Familial and nutritional risk factors for p53 overexpression in colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention, 5:285-291, 1996

Freedman AN, Michalek AM, Marshall JR, Mettlin CJ, Petrelli N, Black JD, Zhang ZF, Satchidanand SKS, and Asirwathan JE. The relationship between smoking history and p53 overexpression in colorectal cancer. British J. Cancer, 73:902-908, 1996

Gangjee A, Mavandadi F, Kisliuk N, McGuire J, Queener S. 2-Amino-4-Oxo-5-Substituted Pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase. J. Med. Chem., 39: 4563-4568, 1996

Greco WR, Faessel H, Levasseur L. The search for cytotoxic synergy between anticancer agents: A case of Dorothy and the ruby slippers?: JNCI, 88:699-700, 1996

Harrison SD, Mihich E, Pearce HL. Editors, Novel anticancer agents for solid tumors - A tribute to Dr. Jerry B. Grindey. Special Issue of Investigational New Drugs, J. New Anticancer Agents, 1996

Hart BP, Haile WH, Licato NJ, Bolanowska WE, McGuire JJ, Coward JK. The synthesis and biologial activity of folic acid and methotrexate analogues containing L-threo (2S,4S)4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid. J. Med. Chem., 39: 56-65, 1996

Helmstetter MF, Maccubbin AE, Alden RW III. The medeka embryo-larval assay: An in vivo assay for toxicity, teratogenicity and carcinogenicity. In Techniques in Aquatic Toxicology. G.K. Ostrander (Ed.) Lewis Publ., CRC Press, Boca Raton, 1996, pp. 93-124

Ip M, Darcy K. Three Dimensional Mammary Primary Culture Model Systems. J. Mam. Gland Biol. & Neoplasia, 1:91-110, 1996

Lin SY, Black AR Kostic A, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle regulated association of E2F1 Sp1 and E2F1 is related to their functional interaction. Mol. Cell. Biol. 16(4):1668-1675, 1996

Matsui S, Arredondo M, Wrzosek C, Rustum YM. DNA damage and p53 induction do not cause of ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res., 56:4715-4723, 1996

McGuire JJ, Haile WH. Potent inhibition of human folylpolyglutamate synthetase by suramin. Arch. Biochem. Biophysics,. 335:139-144, 1996

McGuire JJ, Hart B, Haile W, Magee K, Rhee M, Bolanowska W, Russell C, Galvin J, Paul B, Coward J. Biological properties of fluoroglutamate-containing analogs of folates and methotrexate with altered capacities to form poly(*-glutamate) metabolites. Biochem. Pharm., 52:1295-1303, 1996

McGuire JJ, Tsukamoto T, Hart BP, Coward JK, Kalman TI, Galivan J. Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy. Invest. New Drugs 14:317-323, 1996

Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas, Frank C, Ho DH, Kurowski M, Creaven PJ. A Phase I and pharmacokinetic study of oral uracil, Ftorafur, and leucovorin in patients with advanced cancer, Cancer Chem. & Pharmacol. 37:581-586, 1996

Mihich E, Ehrke MJ. Immunomodulation and cancer therapeutics. In: Recent Advances in Gastroenterological Carcinogenesis I. (Proceedings of the "First International Conference on Gastroenterological Carcinogenesis", Hiroshima, Japan, October 22-24, 1996), E. Tahara, K. Sugimachi, T. Oohara, eds., Monduzzi Editore, 1996, pp. 21-25

Mihich E, Housman D. Eds. Cancer genes - Functional aspects: Seventh Annual Pezcoller Symposium (14-16 June 1995, Trento, Italy), Plenum Press, New York 1996

Mihich E, Housman D. Seventh Annual Pezcoller Symposium: Cancer genes-- Functional aspects, Cancer Res., 56:4282-4287, 1996

Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman D, Wrzosek C, Slovak M, Rustum YM. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry, 25:14-20, 1996

Minderman H, Vanhoefer U, Toth K, Minderman MD, Rustum YM. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance.: Cancer, 78:2427-2436, 1996

Ojima I, Kuduk SD, Slater JC, Gimi RH, Sun CM, Chakravarty S, Ouevitch M, Abouabdellah A, Bonnet-Delphon D, Begue JP, Veith JM, Pera P, Bernacki RJ. Syntheses, biological activity and conformational analysis of fluorine-containing taxoids. In "Biomedical Frontiers of Fluorine Chemistry", ed., Ojima, I., McCarthy, J.R., and Welch, J.T., ACS Symposium Series, 13:639:228-243, 1996

Ojima I, Slater JC, Michaud E, Kuduk SD, Bounaud PY, Vrignaud P, Bissery MC, Veith JM, Pera P, Bernacki RJ. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: Exceptional activity against drug-resistant cancer cells. J.Med.Chem., 39(20):3889-3896, 1996

Packham G, Porter CW, Cleveland JL. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 13:461-469, 1996

Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven P.J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett. 97:177-184, 1996

Porter KG, Saunders PA, Haberyan KA, Maccubbin AE, Jacobsen TR, Hodson RE. Annual cycle of autotropic and heterotrophic production in a small, monomictic Piedmont Lake (Lake Oglethorpe): Analog for the effects of climatic warming on dimictic lakes. Limnol. Oceanog. 41:1041-1051, 1996

Repasky EA, Black JD. Dynamic Properties of the lymphocyte membrane cytoskeleton: Relationship to lymphocyte activation status, signal transduction and protein kinase C. Cur. Top. Memb., 43:313-343, 1996

Rowan BG, Ip MM. Differential binding of mutant glucocorticoid receptors to the glucocorticoid response element of the tyrosine aminotransferase gene. J. Steroid Biochem. Molec. Biol., 58:147-162, 1996

Rustum YM. Pyrimidine Antagonist in Cancer Chemotherapy: In: Encyclopedia of Cancer, J.R. Bertino, ed., Academic Press, Vol. II G-Q, 1997, pp. 1327-1335

Sufrin JR, Rattendi D, Spiess AJ, Lane S, Marasco CJ, Bacchi CJ. The antitrypanosomal activity of purine nucleosides can be enhanced by their conversion to O-acetylated derivatives. Antimicrob. Agents. Chemother., 40:2567-2572, 1996

Toth K, Vaughan M, Peress N, Slocum H, Rustum YM. MDR1 p-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary. Am. J. Pathol., 149:853-858, 1996

Tsukamoto T, Coward JK, McGuire JJ. Fluoroamino acid-containing analogues of folic acid and methorexate. Am. Chem. Soc. Monographs, 639:118-128, 1996

Tsukamoto T, Haile W, McGuire JJ, Coward J. The synthesis and biological evaluation of nalpha-(4-amino-4-deoxy-10-methylpteroyl)-DL-4,4-difluoroornithine. J. Med. Chem., 39:2536-2540, 1996

Tsukamoto T, Kitazume T, McGuire J, Coward J. The synthesis and biological evaluation of DL-4,4-difluoroglutamic acid and DL-*,*-difluoromethotrexate. J. Med. Chem., 39: 66-72, 1996

Ujhazy P, Berleth E, Pietkiewicz J, Kitano H, Skaar S, Ehrke MJ, Mihich E. Evidence for the involvement of ecto-5’-nucleotidase (CD73) in multidrug resistance. Intl. J. Cancer, 68:493-500, 1996. 55. Vanhoefer, U., Cao, S., Minderman, H., Toth, K., Skenderis II, B.S., Slovak, M. and Rustum, Y.M., D,L-Buthionine-(S,R)-sulfoximine potentiates the therapeutic efficiency of doxorubicin against multidrug resistance protein-expressing tumors. Clin. Cancer Res.,2:1961-1968, 1996

Vanhoefer U, Cao S, Minderman H, Toth K, Scheper RJ, Slovak ML, Rustum YM. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin. Cancer Res. 2:369-377, 1996

VanLaar J, Rustum Y, VanderWilt C, Smid K, Pinedo H, Peters G. Tumor size and origin determine antitumor activity of cis-platin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas. Cancer Chemo. and Pharmacol.,. 39:79-89, 1996

Varela L, Ip M. Tumor necrosis factor-*: a multifunctional regulator of mammary gland development. Endocrin.,. 137:4915-4924, 1996

Woynarowska B, Dimitroff CJ, Sharma M, Matta K, Bernacki RJ. Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue. Glycoconjugate J., 13: 663-674, 1996

Ye D, Siddiqi A, Maccubbin A, Kumar S, Sikka H. Degradation of polynuclear aromatic hydrocarbons by Sphingomonas paucimobilis. Environ. Sci. & Technology 30:136-142, 1996